NCT03389347: High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Sponsor: University of Washington. Phase: NA. Conditions: Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma